# BKM120+Abiraterone Acetate for Metastatic CRPC

> **NCT01741753** · PHASE1 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 4 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** BKM120
- **DRUG:** Abiraterone
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT01741753
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-11
- **Primary completion:** 2014-12-29
- **Final completion:** 2016-09-01
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Due to slow accrual the supllier of BKM120 asked we cease further enrollment.
- **Last updated:** 2019-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01741753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01741753, "BKM120+Abiraterone Acetate for Metastatic CRPC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01741753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*